Moroctocog Alfa News
Moroctocog Alfa currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Moroctocog Alfa with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor-VIII deficiency). ReFacto AF is appropriate for use in adults and children of all ages, including newborns....
- Evidence level: L5
- Predicted indications (20):
- primary release disorder of platelets (100.0%)
- pseudo-von Willebrand disease (100.0%)
- Glanzmann thrombasthenia (100.0%)
- hemophilia (99.9%)
- acquired coagulation factor deficiency (99.9%)
- Scott syndrome (99.9%)
- bleeding diathesis due to a collagen receptor defect (99.7%)
- hemorrhagic disorder due to a constitutional thrombocytopenia (99.7%)
- symptomatic form of hemophilia in female carriers (99.4%)
- flood factor deficiency (99.1%)
- hereditary thrombocytosis with transverse limb defect (98.9%)
- familial thrombomodulin anomalies (98.9%)
- inherited thrombophilia (98.7%)
- thrombotic thrombocytopenic purpura (98.6%)
- fetal and neonatal alloimmune thrombocytopenia (98.5%)
- methylcobalamin deficiency type cblG (98.5%)
- platelet-type bleeding disorder (98.1%)
- hemophilia A with vascular abnormality (97.9%)
- factor XI deficiency (97.5%)
- Ehlers-Danlos syndrome, fibronectinemic type (97.3%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.